Fig. 6

Calibration curves and decision curve analysis of the nomograms in the training and validation cohorts. Calibration curves for the estimation of model 2 (Combining tumor c, tumor φ, cirrhosis, hepatitis virus, rim APHE, peritumoral enhancement, and tumor margin) predicted by the nomogram in the training cohort (a) and in the validation cohort (b). The x-axis indicates the predicted probability. The y-axis measures the actual probability. The blue line represents the performance of the nomogram, whereas the red line corrects for any bias in the nomogram. The dashed line represents the reference line where an ideal nomogram would lie. Decision curve analysis (DCA) of model 1 (Combining cirrhosis, hepatitis virus, rim APHE, peritumoral enhancement, and tumor margin) and model 2 in the training cohort (c) and in the validation cohort (d) indicated their clinical net benefits. The x-axis represents the threshold probability. The y-axis indicates the net benefit. The gray line shows the net benefit of proliferative HCCs. The blue and red lines represented model 1 and model 2 of nomograms, respectively. DCA indicated their clinical net benefits. DCA showed that the model 2 gained more clinical net benefit than the model 1 in both training and validation cohorts. APHE: arterial phase hyperenhancement